{
  "emaEpar": [
    {
      "activeSubstance": "degarelix",
      "conditionIndication": "Firmagon is a gonadotrophin-releasing-hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer.",
      "inn": "degarelix",
      "marketingAuthorisationDate": "2009-02-17 01:00:00",
      "marketingAuthorisationHolder": "Ferring Pharmaceuticals A/S",
      "medicineName": "Firmagon",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon"
    }
  ],
  "fdaDrugLabel": [],
  "id": "Degarelix",
  "nciThesaurus": {
    "casRegistry": "214766-78-6",
    "chebiId": "",
    "chemicalFormula": "C82H103ClN18O16",
    "definition": "A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.",
    "fdaUniiCode": "SX0XJI3A11",
    "identifier": "C48385",
    "preferredName": "Degarelix",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C2092"
    ],
    "synonyms": [
      "DEGARELIX",
      "Degarelix",
      "FE200486",
      "Firmagon",
      "N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide",
      "degarelix"
    ]
  }
}